Connect with us

Business

AstraZeneca teams up with Chinese firm in $18.5bn deal for weight loss drugs

Published

on

Business Live

The FTSE 100 pharmaceutical giant will have access to exclusive global rights, outside China, to CSPC’s once-a-month dose technology for experimental weight management treatments

Corporate logos are seen outside the Macclesfield factory of AstraZeneca

AstraZeneca has major UK hubs in Cambridge and Macclesfield(Image: Getty Images)

AstraZeneca has announced a strategic partnership with China’s CSPC Pharmaceutical Group valued at 18.5 billion US dollars (£13.4 billion) to accelerate the development of experimental weight loss and diabetes treatments, as the pharmaceutical giant seeks to expand its presence in the rapidly growing weight management market.

Advertisement

The agreement grants the FTSE 100 company exclusive worldwide rights, excluding China, to CSPC’s monthly-dose technology portfolio for weight management, providing an alternative to daily injections currently on the market.

The partnership will extend to four additional programmes, using CSPC’s advanced platforms for long-acting technology and artificial intelligence-driven peptide drug discovery.

Sharon Barr, executive vice president and head of biopharmaceuticals research and development at AstraZeneca, said: “This strategic collaboration advances our weight management portfolio by delivering novel assets which complement our existing programmes.”

She added: “It will provide access to CSPC’s proprietary, AI-enabled, peptide capabilities and platform technology, which have the potential to transform the treatment of obesity, helping to address adherence and convenience as key barriers to long-term therapeutic success.

Advertisement

“This is an important step in creating a portfolio of simple, scalable and sustainable options that can help people with obesity, and weight-related complications live better, healthier lives.”

Dongchen Cai, chairman of CSPC, described the arrangement as a “win-win collaboration”. He said the agreement will enable the companies to “deliver the next generation of treatments that build upon the emerging science, using our technology platforms and AstraZeneca’s complementary capabilities and reach, to realise global health benefits for people in need of improved weight management”.

This represents the latest collaboration between the two firms, who have previously partnered on projects such as artificial intelligence (AI). In exchange for access to eight weight loss programmes in total, AstraZeneca will pay CSPC an upfront fee of 1.2 billion dollars (£870 million), with up to a further 17.3 billion dollars (£12.6 billion) contingent on development and sales milestones being achieved.

The deal is anticipated to be finalised in the second quarter. This move sees AstraZeneca increase its investment into the rapidly expanding market for weight loss and diabetes drugs, which has hitherto been dominated by blockbuster brands Mounjaro, Ozempic and Wegovy.

Advertisement

According to AstraZeneca, it is estimated that nearly three billion people worldwide are obese or overweight. The company said obesity was a “chronic, relapsing, multifactorial disease and contributes to over 200 complications”.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

OpenClaw founder Steinberger joins OpenAI, open-source bot becomes foundation

Published

on

OpenClaw founder Steinberger joins OpenAI, open-source bot becomes foundation


OpenClaw founder Steinberger joins OpenAI, open-source bot becomes foundation

Continue Reading

Business

Waystar Holding Corp.: A Lot Of Market Share Yet To Convert, In An Ever-Growing Market.

Published

on

Waystar Holding Corp.: A Lot Of Market Share Yet To Convert, In An Ever-Growing Market.

Waystar Holding Corp.: A Lot Of Market Share Yet To Convert, In An Ever-Growing Market.

Continue Reading

Business

JFrog: A Mission-Critical Platform Driving Strong Unit Economics

Published

on

JFrog: A Mission-Critical Platform Driving Strong Unit Economics

JFrog: A Mission-Critical Platform Driving Strong Unit Economics

Continue Reading

Business

Australian takeover target BlueScope beats estimate with first-half earnings

Published

on

Australian takeover target BlueScope beats estimate with first-half earnings


Australian takeover target BlueScope beats estimate with first-half earnings

Continue Reading

Business

Treasury Wine’s first-half profit halves, interim dividend suspended

Published

on

Treasury Wine’s first-half profit halves, interim dividend suspended


Treasury Wine’s first-half profit halves, interim dividend suspended

Continue Reading

Business

New Zealand home prices dip in January, holiday lull hits demand

Published

on

New Zealand home prices dip in January, holiday lull hits demand


New Zealand home prices dip in January, holiday lull hits demand

Continue Reading

Business

FBI confirms DNA recovered from glove found near Nancy Guthrie’s home

Published

on

FBI confirms DNA recovered from glove found near Nancy Guthrie’s home


FBI confirms DNA recovered from glove found near Nancy Guthrie’s home

Continue Reading

Business

New Zealand’s a2 Milk posts 9.4% rise in interim earnings

Published

on

New Zealand’s a2 Milk posts 9.4% rise in interim earnings


New Zealand’s a2 Milk posts 9.4% rise in interim earnings

Continue Reading

Business

Warner Bros weighs reopening sale talks with Paramount, Bloomberg News reports

Published

on

Warner Bros weighs reopening sale talks with Paramount, Bloomberg News reports


Warner Bros weighs reopening sale talks with Paramount, Bloomberg News reports

Continue Reading

Business

PCE, Walmart, Palo Alto, Analog Devices, Deere, and More to Watch This Week

Published

on

PCE, Walmart, Palo Alto, Analog Devices, Deere, and More to Watch This Week

PCE, Walmart, Palo Alto, Analog Devices, Deere, and More to Watch This Week

Continue Reading

Trending

Copyright © 2025